Cellromax Science Co

Cellromax Science Co Debt/EBITDA

The Total Debt to EBITDA Ratio of Cellromax Science Co (471820.KQ) as of Nov 6, 2026 is 0.17.

Debt/EBITDA

0.17

Last updated:

Total Debt to EBITDA Ratio of Cellromax Science Co is 2024 0.17 . Total Debt to EBITDA Ratio of Cellromax Science Co was 2023 - . It decreases by % lower compared to the previous year.

The Cellromax Science Co Debt/EBITDA history

The Cellromax Science Co Debt/EBITDA history
YEARDebt/EBITDAYoY
0.17—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellromax Science Co Stock analysis

What does Cellromax Science Co do? Cellromax Science Co Ltd generates revenue through the development and distribution of health functional foods, functional cosmetics, and general medicines. The company's primary brand, 'Cellromax,' targets consumers seeking health and wellness solutions. Its products are sold to customers interested in health-focused lifestyle choices, including those purchasing functional foods and cosmetics for daily use. The firm operates within the health and wellness sector, focusing on product innovation and consumer demand for natural health solutions. The company's business model centers around its brand 'Cellromax,' which is used across its health functional food and cosmetic product lines. Revenue is derived from direct sales of these branded products to end consumers. The firm's focus on functional foods and cosmetics positions it within the health and wellness market segment, catering to individuals prioritizing health maintenance and beauty enhancement through scientifically backed products. Cellromax Science Co Ltd's product portfolio includes health functional foods, functional cosmetics, and general medicines. The company distributes these items through retail channels to consumers seeking health and beauty solutions. Its brands, particularly 'Cellromax,' drive customer engagement and sales, with the company emphasizing product quality and scientific validation to attract health-conscious buyers in the Korean market. Cellromax Science Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellromax Science Co stock

Total Debt to EBITDA Ratio of Cellromax Science Co is 0.17 in 2024.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Cellromax Science Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Cellromax Science Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cellromax Science Co

All Key Metrics — Cellromax Science Co